New Paper on Model Development for MDR Pseudomonas

SEPTEMBER 12, 2022

In the latest issue of Microbiology Spectrum, we and our collaborators report on the development of a preclinical model to test drugs against multidrug-resistant Pseudomonas aeruginosa.

The prevalence of antibiotic resistance among bacterial pathogens is a growing problem that necessitates the development of new antibiotics. Preclinical animal models are important tools to facilitate and speed the development of novel antimicrobials. Successful outcomes in animal models not only justify progression of new drugs into human clinical trials but also can support FDA decisions if clinical trial sizes are small due to a small population of infections with specific drug-resistant strains. However, in both cases the preclinical animal model needs to be well characterized and provide robust and reproducible data.

Toward this goal, we refined an existing mouse model to better predict the efficacy of novel antibiotics. This improved model provides an important tool to better predict the clinical success of new antibiotics.

Read the paper here.